Jean Publicover

Jean Publicover

Auto-generated profile, based on publicly available information

Jean Publicover

Department of Medicine and Liver Center, University of California, San Francisco, San Francisco, CA 94143, USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 October 2018 in JCI Insight
Verified
Journal Article
Closed access
PDF file
NTNaoki Takasaka
Naoki Takasaka
RSRobert Seed
Robert Seed
ACAnthony Cormier
Anthony Cormier
ABAndrew J. Bondesson
Andrew J. Bondesson
Jianlong LouJianlong Lou
Jianlong Lou
SNStephen L. Nishimura
Stephen L. Nishimura
TGF-β is a promising immunotherapeutic target. It is expressed ubiquitously in a latent form that must be activated to function. Determination of where and how latent TGF-β (L-TGF-β) is activated in the tumor microenvironment could facilitate cell- and mechanism-specific approaches to immunotherapeutically target TGF-β. Binding of L-TGF-β to integrin αvβ8 results in activation of TGF-β. We engineered and used αvβ8 antibodies optimized for blocking or detection, which — respectively — inhibit tumor growth in syngeneic tumor models or sensitively and specifically detect β8 in human tumors. Inhibition of αvβ8 potentiates cytotoxic T cell responses and recruitment of immune cells to tumor centers — effects that are independent of PD-1/PD-L1. β8 is expressed on the cell surface at high levels by tumor cells, not immune cells, while the reverse is true of L-TGF-β, suggesting that tumor cell αvβ8 serves as a platform for activating cell-surface L-TGF-β presented by immune cells. Transcriptome analysis of tumor-associated lymphoid cells reveals macrophages as a key cell type responsive to β8 inhibition with major increases in chemokine and tumor-eliminating genes. High β8 expression in tumor cells is seen in 20%–80% of various cancers, which rarely coincides with high PD-L1 expression. These data suggest tumor cell αvβ8 is a PD-1/PD-L1–independent immunotherapeutic target.

21 March 2018 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
JPJean Publicover
Jean Publicover
AGAnuj Gaggar
Anuj Gaggar
JJJillian M. Jespersen
Jillian M. Jespersen
UHUgur Halac
Ugur Halac
AJAudra J. Johnson
Audra J. Johnson
JBJody L. Baron
Jody L. Baron
Depending on age of acquisition, hepatitis B virus (HBV) can induce a cell-mediated immune response that results in either cure or progressive liver injury. In adult-acquired infection, HBV antigens are usually cleared, whereas in infancy-acquired infection, they persist. Individuals infected during infancy therefore represent the majority of patients chronically infected with HBV (CHB). A therapy that can promote viral antigen clearance in most CHB patients has not been developed and would represent a major health care advance and cost mitigator. Using an age-dependent mouse model of HBV clearance and persistence in conjunction with human blood and liver tissue, we studied mechanisms of viral clearance to identify new therapeutic targets. We demonstrate that age-dependent expression of the costimulatory molecule OX40 ligand (OX40L) by hepatic innate immune cells is pivotal in determining HBV immunity, and that treatment with OX40 agonists leads to improved HBV antigen clearance in young mice, as well as increased strength of T cell responses in young mice and adult mice that were exposed to HBV when they were young and developed a CHB serological profile. Similarly, in humans, we show that hepatic OX40L transcript expression is age-dependent and that increased OX40 expression on peripheral CD4+ T cells in adults is associated with HBV clearance. These findings provide new mechanistic understanding of the immune pathways and cells necessary for HBV immunity and identify potential therapeutic targets for resolving CHB.

4 March 2021 in Science Immunology
Verified
Journal Article
Closed access
PDF file
RSRobert Seed
Robert Seed
KKKenji Kobayashi
Kenji Kobayashi
SISaburo Ito
Saburo Ito
NTNaoki Takasaka
Naoki Takasaka
ACAnthony Cormier
Anthony Cormier
SNStephen L. Nishimura
Stephen L. Nishimura
Tumor cells expressing integrin αvβ8 activated latent TGF-β on T cells, inducing T reg enrichment and tumor immunosuppression.